Author:
McCann Sue A.,Story Sara K.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Advanced and Specialised Nursing
Reference13 articles.
1. Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma: Results of a phase II study.;Advani;Blood (ASH Annual Meeting Abstracts),2007
2. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.;de Bono;Clinical Cancer Research,2008
3. Mycosis fungoides and Sezary syndrome: The burden of pruritus.;Demierre;Community Oncology,2010
4. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).;Duvic;Blood,2007
5. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.;Giles;Clinical Cancer Research,2006
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献